Friday, July 10, 2026

Drug profile · INN

glargine

glargine is a insulin receptor agonist.

NMPA: clinical trials
Patents linked 0
Pipeline programs 12
News articles 0
Drug details — glargine
Class
Route
Patents
0
Programs
12
Data quality
0.70

Quick answer

glargine is a insulin receptor agonist.

Key facts

INN glargine
Mechanism Insulin receptor agonist
Target Insulin receptor

Mechanism of action

Insulin receptor agonist

Primary target: Insulin receptor

Approval history

Authority Status Date
NMPA clinical trials

Pipeline programs

  1. Glargine Phase 3 · Eli Lilly and · Diabetes Mellitus, Type 2
  2. Insulin glargine/Lixisenatide (HOE901/AVE0010) Phase 3 · Sanofi Pasteur MSD · Type 2 Diabetes Mellitus
  3. J2A-MC-GZGW Phase 3 · Eli Lilly and · Type 2 Diabetes
  4. NN9388-7637 Phase 3 · NovoThirteen · Type 2 diabetes
  5. albiglutide + insulin glargine Phase 3 · GSK Glaxo Smith · Diabetes Mellitus, Type 2
  6. BioPhenoT2D Approved · Telethon Foundation · type 2 diabetes
  7. INSULIN GLARGINE Approved · Sanofi-Aventis U.S · Diabetes mellitus II
  8. INSULIN GLARGINE (HOE901) Approved · Sanofi Pasteur MSD · Diabetes Mellitus, Type 2

Related & competitor drugs

  1. insulin aspart Alimentary tract and metabolism (A10)
  2. insulin aspart protamine recombinant Insulin receptor agonist
  3. insulin aspart recombinant Insulin receptor agonist
  4. insulin degludec Alimentary tract and metabolism (A10)
  5. insulin detemir Alimentary tract and metabolism (A10)
  6. insulin detemir recombinant Insulin receptor agonist

Frequently asked questions

What is glargine?

glargine is a insulin receptor agonist.